Filing Flows › Maze Therapeutics (MAZE) › Recalls, complaints & regulation
Maze Therapeutics (MAZE): clinical trials
Maze Therapeutics (MAZE) beyond its filings: 2 active clinical trials.
Maze Therapeutics' latest quarter
Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Maze Therapeutics have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.